MARKET OUTLOOK
Triton’s report has determined the European ophthalmology drugs and devices market to flourish at a compound annual growth rate of 5.99% throughout the forecast duration of 2019-2027.
The United Kingdom, France, Germany, Spain, Italy, Russia and countries in rest of Europe together comprise the market for ophthalmology drugs and devices in the European region.
The Germany ophthalmological drugs and devices market is mainly driven by the highest healthcare expenditure by the country in the entire European region, along with the initiatives taken by the private organizations considering the development & growth of ophthalmology in the country. According to company sources, Optegra Organizations, an international provider of eye surgery has acquired Memira Organization’s operations, aiming to provide ophthalmological services across the urban and semi-urban provinces of the country, that include the ophthalmology clinics in Stuttgart and Munich. The Optegra Organization provides general ophthalmology services in many ranges of eye applications which include retinal, glaucoma, orbitofacial and corneal. According to the Organization for Economic Cooperation and Development, the healthcare expenditure of Germany accounted for $5,119 per capita in 2014, which reached at $5,267 per capita in 2015, that may support various researches in ophthalmology, which positively influences the growth of the ophthalmology drugs and devices market in Germany.
COMPETITIVE OUTLOOK
The biggest brands in the market are Novartis International AG, Pfizer, Roche Holding AG, Santen Pharmaceutical Co., Ltd., Sun Pharmaceuticals Industries, Ltd., Valeant Pharmaceuticals International, Inc. and Ziemer Group Holding AG.